SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. – ALLK

NEW YORK, NY / ACCESSWIRE / December 21, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or the "Company") (NASDAQ:ALLK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Allakos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On December 18, 2019, Seligman Research ("Seligman") published a report characterizing Allakos as "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud." Among a litany of other issues, the Seligman report accused Allakos of having "buried the results for the two AK001 studies it conducted, but our research indicates a debacle"; having "a checkered history of conducting small, low-credibility trials, marked by a striking level of what we consider to be discrepancies, omissions, cherry-picking, and other red flags"; and engaging in "[f]lagrant nepotism in key clinical roles".

On this news, Allakos's stock price fell $13.25 per share, or 10%, to close at $119.28 on December 18, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 571006